CTSO (Cytosorbents Corp.)
Insider Trading Activity
Every open-market purchase and sale reported by CTSO officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-16 | Alan D. Sobel | Director | Buy | — | — |
| 2026-09-16 | Phillip P. Chan | Chief Executive Officer | Buy | — | — |
| 2026-09-16 | Vincent Capponi | President and COO | Buy | — | — |
| 2026-09-09 | Phillip P. Chan | Chief Executive Officer | Buy | — | — |
| 2026-06-16 | PETER J MARIANI | Chief Financial Officer | Buy | — | — |
| 2026-06-15 | Phillip P. Chan | Chief Executive Officer | Buy | — | — |
| 2025-11-20 | Phillip P. Chan | Chief Executive Officer | A | — | — |
| 2025-08-08 | Edward Raymond Jones | Director | A | — | — |
| 2025-08-08 | Vincent Capponi | President and COO | A | — | — |
| 2025-08-08 | Phillip P. Chan | Chief Executive Officer | A | — | — |
| 2025-08-08 | MICHAEL G. BATOR | Director | A | — | — |
| 2025-08-08 | PETER J MARIANI | Chief Financial Officer | A | — | — |
| 2025-08-08 | Jiny Kim | Director | A | — | — |
| 2025-08-08 | Alan D. Sobel | Director | A | — | — |
| 2025-08-08 | Efthymios Deliargyris | Chief Medical Officer | A | — | — |
| 2025-03-04 | MICHAEL G. BATOR | Director | O | — | — |
| 2025-02-26 | Phillip P. Chan | Chief Executive Officer | O | — | — |
| 2025-02-26 | Vincent Capponi | President and COO | O | — | — |
| 2025-02-26 | PETER J MARIANI | Chief Financial Officer | O | — | — |
| 2025-02-26 | Alan D. Sobel | Director | O | — | — |
| 2025-01-22 | MICHAEL G. BATOR | Director | X | — | — |
| 2025-01-22 | PETER J MARIANI | Chief Financial Officer | X | — | — |
| 2025-01-22 | Efthymios Deliargyris | Chief Medical Officer | X | — | — |
| 2025-01-22 | Alan D. Sobel | Director | X | — | — |
| 2025-01-22 | Vincent Capponi | President and COO | X | — | — |
| 2025-01-22 | Phillip P. Chan | Chief Executive Officer | X | — | — |
| 2024-12-16 | PETER J MARIANI | Chief Financial Officer | Buy | — | — |
| 2024-12-13 | PETER J MARIANI | Chief Financial Officer | Buy | — | — |
| 2024-10-08 | Vincent Capponi | President and COO | A | — | — |
| 2024-10-08 | Efthymios Deliargyris | Chief Medical Officer | A | — | — |
| 2024-08-16 | PETER J MARIANI | Chief Financial Officer | A | — | — |
| 2024-04-04 | Alan D. Sobel | Director | A | — | — |
| 2024-04-04 | MICHAEL G. BATOR | Director | A | — | — |
| 2024-04-04 | Edward Raymond Jones | Director | A | — | — |
| 2024-04-04 | Efthymios Deliargyris | Chief Medical Officer | A | — | — |
| 2024-04-04 | KATHLEEN P. BLOCH | Chief Financial Officer | A | — | — |
| 2024-04-04 | Vincent Capponi | President and COO | A | — | — |
| 2024-04-04 | Phillip P. Chan | Chief Executive Officer | A | — | — |
| 2024-04-04 | Jiny Kim | Director | A | — | — |
| 2024-04-02 | Efthymios Deliargyris | Chief Medical Officer | A | — | — |
| 2024-04-02 | KATHLEEN P. BLOCH | Chief Financial Officer | A | — | — |
| 2024-04-02 | Phillip P. Chan | Chief Executive Officer | A | — | — |
| 2024-04-02 | Vincent Capponi | President and COO | A | — | — |
| 2023-12-15 | KATHLEEN P. BLOCH | Chief Financial Officer | Buy | — | — |
| 2023-12-15 | Alan D. Sobel | Director | Buy | — | — |
| 2023-12-15 | Jiny Kim | Director | Buy | — | — |
| 2023-12-15 | Efthymios Deliargyris | Chief Medical Officer | Buy | — | — |
| 2023-12-15 | Edward Raymond Jones | Director | Buy | — | — |
| 2023-12-15 | MICHAEL G. BATOR | Director | Buy | — | — |
| 2023-12-15 | Vincent Capponi | President & COO | Buy | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | 10%+ Owner | 183,761 | — |
| — | Chief Executive Officer | 100,996 | — |
| — | President and COO | 40,114 | — |
| — | Chief Financial Officer | 31,906 | — |
| — | Chief Financial Officer | 28,997 | — |
| — | Chief Medical Officer | 23,651 | — |
| — | Director | 9,387 | — |
| — | Director | 7,564 | — |
| — | Chief Medical Officer | 7,447 | — |
| — | Director | 7,102 | — |
| — | Director | 4,442 | — |
| — | Director | 3,891 | — |
| — | Director | 2,750 | — |
| — | Chief Medical Officer | 1,500 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the CTSO quote page; the site-wide leaderboard is on the insider transactions hub.